Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

DOD Lung Cancer Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

April 12, 2024

Vol.50 No.15

Clinical Roundup

Imfinzi improves OS and PFS in limited-stage LS-SCLC in phase III trial

In the phase III ADRIATIC trial, Imfinzi (durvalumab) showed a statistically significant and clinically meaningful improvement in overall survival and progression-free survival for patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy, compared to placebo after cCRT.

April 12, 2024

Vol.50 No.15

Clinical Roundup

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.

April 12, 2024

Vol.50 No.15

In Brief

UT Southwestern Moncrief Cancer Institute debuts second mobile screening clinic funded by Tarrant County

University of Texas Southwestern Moncrief Cancer Institute debuted its second Mobile Screening Clinic prior to the Tarrant County Commissioners Court meeting.

March 29, 2024

Vol.50 No.13

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

In Brief

Vittoria Bocchi, Julia Brunner, Melissa Yao, Tzippora Chwat-Edelstein named 2024 Kravis WiSE fellows

From left to right: Vittoria Bocchi, Melissa Yao, Julia Brunner, Tzippora Chwat-EdelsteinVittoria Bocchi, Julia Brunner, Melissa Yao, and Tzippora Chwat-Edelstein, four Sloan Kettering Institute researchers, were named 2024 Marie-Josée Kravis Women in Science Endeavor, or Kravis WiSE, fellowship grant recipients.

March 08, 2024

Vol.50 No.10

Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer

Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

YOU MAY BE INTERESTED IN

DOD Lung Cancer Research Program funding opportunities for FY24

Imfinzi improves OS and PFS in limited-stage LS-SCLC in phase III trial

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

UT Southwestern Moncrief Cancer Institute debuts second mobile screening clinic funded by Tarrant County

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

Vittoria Bocchi, Julia Brunner, Melissa Yao, Tzippora Chwat-Edelstein named 2024 Kravis WiSE fellows

Renew today!

Subscriber content

Login